Korean journal of clinical oncology最新文献

{"title":"Association between bioelectrical impedance analysis and platelet-to-lymphocyte ratio in colorectal cancer","authors":"J. Kim","doi":"10.14216/KJCO.19001","DOIUrl":"https://doi.org/10.14216/KJCO.19001","url":null,"abstract":"","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"127 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74312179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid progression of sarcomatoid carcinoma of the common bile duct","authors":"Moon Jin Kim, Jun Suh Lee, Yu Mi Kim, Soyeon An, Y. Yoon","doi":"10.14216/KJCO.19008","DOIUrl":"https://doi.org/10.14216/KJCO.19008","url":null,"abstract":"narrowing in mid CBD (Fig. 1). Brush cytology smears from the distal bile duct showed atypical cell, suggesting adenocarcinoma. We did not perform liver mag-netic resonance imaging because there was no suspicion of liver metastasis on CT. Preoperative imaging stage was T2 or T3N0M0. Since sarcomatoid carcinoma in the common bile duct (CBD) is rarely reported, the clinical course and prognosis after surgery are unclear. We report a case of a patient who died within 1 month after surgery due to rapid tumor progression. A 65-year-old woman had abdominal pain with jaundice. She was diagnosed with CBD cancer and underwent pancreatoduodenectomy. Pathologic examination revealed sarcomatoid carcinoma. There was no postoperative complication, but multiple liver metastasis was diagnosed on computed tomography at 7 days after surgery. Also, the patient complained of abdominal pain and had jaundice with elevated liver enzyme on the 14th postoperative day. Her general condition was getting worse and she died of hepatic failure 23 days after surgery. We report a case of sarcomatoid carcinoma of the CBD that progressed very rapidly. Further research and case reports are needed to establish proper diagnostic and treatment tools.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77768772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bevacizumab induced intestinal perforation in patients with colorectal cancer","authors":"Sun-Young Baek, Seung Hun Lee, Seung-Hyun Lee","doi":"10.14216/KJCO.19004","DOIUrl":"https://doi.org/10.14216/KJCO.19004","url":null,"abstract":"Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor, is an antiangiogenic agent approved for the treatment of multiple solid tumors. It has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy [1]. With increased use of bevacizumab, serious adverse effects are being reported more frequently, including hypertension, proteinuria, hemorrhage, thrombosis, fistula formation, and bowel perforation [24]. In two phase 3 trials of bevacizumab in colorectal cancer, intestinal perforation was an uncommon adverse event occurring at rates of only 1.5% and 1.1%, though serious and lethal. Here, the purpose of this study is to identify the clinical characteristics of intestinal perforation induced by bevacizumab in colorectal cancers.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88036796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of lymph node count on survival in gastric cancer","authors":"H. Ahn, Se Wung Han, D. Yang, C. Kim","doi":"10.14216/KJCO.18021","DOIUrl":"https://doi.org/10.14216/KJCO.18021","url":null,"abstract":"The Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) classifies the N stage of gastric cancer based on the metastatic lymph node (LN) count [1,2]. N stage is important for determining treatment strategies and predicting prognosis along with tumor depth (pT stage), and harvesting more than 15 LNs is recommended for proper N staging. Inappropriate LN count results in an inappropriate node-negative result, leading to a lower overall stage, referred to as stage migration. Stage migration shows a worse survival than that of appropriately assessed LN count. However, a large LN count shows better prognosis, suggesting the prognostic significance of the LN count. Most of surgeons agree on the extent of LN dissection, which minimizes stage migration, in order to compare prognosis. Experienced surgeons not only perform LN dissection but also perform LN harvest for pathological examination. In Korea and Japan, D2 LN dissection is the standard LN dissection guideline for gastric cancer, and gastric surgeries are performed by experienced surgeons at hospitals specializing in gastric cancer surgery. There is a tendency to perform LN harvest during surgery, minimizing the possibility of missing positive LNs. Recently, suspicions have been raised that stage migration is exaggerated in meta-analysis studies, arguing that although there is evidence that fat clearance and methylene blue staining during LN harvest increases LN count [2], there is no evidence that this increases LN positivity and upstaging [3]. Some studies also reported that LN count is an indicator for host immunologic role against tumor dissemination [4]. However, there is no direct evidence, and more studies need to be conducted. The purpose of this study was to determine the immunologic role of LN and stage migration by assessing LN count and metastatic LN count. Original Article Korean Journal of Clinical Oncology 2018;14:120-127 https://doi.org/10.14216/kjco.18021 pISSN 1738-8082 ∙ eISSN 2288-4084","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91282434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic correlation with MUC expression in advanced gastric cancer","authors":"Kwang Kim, K. W. Choi, W. Lee","doi":"10.14216/KJCO.18016","DOIUrl":"https://doi.org/10.14216/KJCO.18016","url":null,"abstract":"The qualitative and quantitative alteration of mucin expression in preneoplastic and neoplastic lesions has indicated its potential roles in neoplastic processes, as reviewed by Cozzi et al. [1]. Furthermore, numerous pieces of evidence indicate a close association between aberrant mucin expression and aggressive malignancies. Recently, various mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC6, MUC7, and MUC8) have been used to evaluate the mucin phenotypes associated with gastric cancer [2]. Normal gastric mucosa shows cell type specific expression of MUC1, MUC5AC, and MUC6 with first two mucins found in the superficial epithelium and MUC6 in the deep glands [3-5]. Normal gastric mucosa does not express MUC2 and de novo expression begins in the intestinal metaplasia [4,6]. Alteration of mucin expression happens in gastric carcinomas and it was reported that gastric carcinomas contain a higher level of MUC1 expression than normal gastric mucosa. In contrast to the increased expression of MUC1 and MUC2, MUC5AC, and MUC6 expression decreased during gastric carcinogenesis. Controversies and conflicting data exist among studies that elucidated the relationship between the changes in mucin expression and the effect on prognosis and there is no absolute study showing the alteration of mucin expression in different histologic types. The primary purpose of this study was to determine the relationship between MUC1, MUC2, MUC5AC, and MUC6 expresOriginal Article Korean Journal of Clinical Oncology 2018;14:89-94 https://doi.org/10.14216/kjco.18016 pISSN 1738-8082 ∙ eISSN 2288-4084","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"226 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89187647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing trends in clinico-pathologic characteristics and treatment outcomes in patients with gastric cancer: A single-center, public hospital, retrospective study","authors":"Min Gwak, Jong-Min Park","doi":"10.14216/KJCO.18013","DOIUrl":"https://doi.org/10.14216/KJCO.18013","url":null,"abstract":"Gastric cancer (GC) is known as the 5th most common malignancy, and it is also the 3rd leading cause of death worldwide [1]. Despite a recent decline in its incidence in developed countries, 1.3 million patients are annually diagnosed with GC. This is also accompanied by a report of 819,000 cases of deaths in 2015 [2]. In Korea, GC is the 2nd most prevalent cancer and the 3rd leading cause of death [3]. Despite considerable advancements in outcomes of GC treatment, accompanied by improved prognosis, which are attributable to early diagnosis, radical operation and development of adjuvant therapies, its poor prognosis remains worrisome [4]. Over several decades, there have been great advancements in treatment modalities and strategies for patients with GC. This is accompanied by recent trends in which treatment approaches have been customized to both patient and tumor characteristics [5]. Furthermore, there have been dramatic changes in treatment strategy, which is mainly due to advances in chemotherapy. Still, however, curative surgery remains a main stay of treatment for patients with GC. There is a variability in the survival rate depending on Original Article Korean Journal of Clinical Oncology 2018;14:69-75 https://doi.org/10.14216/kjco.18013 pISSN 1738-8082 ∙ eISSN 2288-4084","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91005071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer","authors":"Ashraf M. El-Enbaby, N. A. E. Moneim, G. Khedr, Yasmine Mohamed Nagy Elwany","doi":"10.14216/KJCO.18019","DOIUrl":"https://doi.org/10.14216/KJCO.18019","url":null,"abstract":"Breast cancer is considered a major public health problem for women throughout the world. In the United States, breast cancer is still the most frequently diagnosed cancer in women and the 2nd most frequent cause of cancer mortality [1]. Worldwide, breast cancer is the most frequently diagnosed cancer and the leading cause of cancer mortality among females, accounting for 23% of total cancer cases and 14% of cancer deaths, however, there is a 5-fold variation in incidence between high-incidence areas such as the United States and Western Europe, and low incidence areas such as Africa and Asia [1]. In Egypt, breast cancer is estimated to be the most common cancer among females accounting for 37.7% in 2008. It is also the leading cause of cancer related mortality accounting for 29.1% of their total. The incidence to mortality ratio is poor (1.9:1). These estimates are confirmed in many regional Egyptian cancer registries as well as in hospital-based frequencies [2-4]. Women presenting with abnormal imaging findings alone should undergo biopsy guided by mammography (stereotactic biopsy or wire localization breast biopsy), ultrasound, or breast magnetic resonance imaging. Women presenting with a breast mass should undergo fine needle aspiration or core needle biopsy. Newly diagnosed breast cancer cases should be tested for by estrogen receptor (ER) and progesterone receptor (PR) expression and for Original Article Korean Journal of Clinical Oncology 2018;14:108-115 https://doi.org/10.14216/kjco.18019 pISSN 1738-8082 ∙ eISSN 2288-4084","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79791342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences of thoracic esophagectomy with laparoscopic gastric pull up in thoracic esophageal cancer patient in single center","authors":"Jin Jun, Wooshik Kim, Jong-Min Park","doi":"10.14216/KJCO.18017","DOIUrl":"https://doi.org/10.14216/KJCO.18017","url":null,"abstract":"Metastasis of esophageal cancer to adjacent organs commonly occurs due to the esophagus’ anatomical characteristic, wherein the serosa is absent, thereby making the surgical treatment difficult at the time of discovery. Nevertheless, when operable esophageal cancer is diagnosed, the gold standard for treatment is the Ivor-Lewis operation, which consists of esophagectomy, esophageal reconstruction, and anastomosis. The ideal conduit used for esophageal reconstruction should be an organ, requiring a relatively simple surgical technique, with similar size and function of the original esophagus, and with minimal complications after surgery [1]. The stomach has advantages over other organs like the colon and jejunum, such as appropriate length, lesser deviation in blood flow supply, easy to operate, and only requires a single anastomosis [2,3]. Since the introduction of minimally invasive esophagectomy in the 1990s, video-assisted thoracic surgery has been widely used [4], though our center currently uses open esophagectomy and laparoscopic gastric pull up (LGPU). Laparoscopic surgery is widely used owing to its variety of benefits, such as reduced hospital stay, reduced postoperative pain, and better cosmetic aspect, since laparoscopic cholecystectomy surgery was introduced [5]. Our center utilized the open gastric pull-up method after esophagectomy in esophageal cancer treatment until May 2008. Conventional open Original Article Korean Journal of Clinical Oncology 2018;14:95-101 https://doi.org/10.14216/kjco.18017 pISSN 1738-8082 ∙ eISSN 2288-4084","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"245 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80592223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant chemotherapy in patients with stage II colon cancer","authors":"H. J. Kim","doi":"10.14216/KJCO.18012","DOIUrl":"https://doi.org/10.14216/KJCO.18012","url":null,"abstract":"67 The purpose of adjuvant chemotherapy after curative resection of colon cancer is eradication of micrometastatic disease, decreasing the recurrence and improving the overall survival. However, chemotherapy may have risk of side effects, and decrease the quality of life. Therefore, the decision making to adding chemotherapy should be made under considering the balance between the risk of recurrence and chemotherapy. The advantage of adjuvant chemotherapy in stage III colon cancer is well proven by many randomized controlled trials and now it is regarded as a standard treatment [1]. As for the regimen, traditional 5-fluorouracil (5-FU) and leucovorin, capecitabine monotherapy, FOLFOX, or CAPOX are recommended. However, in stage II colon cancer, if the curative resection was performed, the prognosis is very good and the overall survival after curative resection is reported around 80% [2,3]. The role of adjuvant chemotherapy in stage II colon cancer is minimal and remains an area of great controversy [4]. And which patients will benefit from adjuvant chemotherapy and what chemotherapy to use also remain an area of great controversy. Because patients with stage II colon cancer comprise a heterogeneous combination including stage IIA (pT3N0), stage IIB (pT4aN0), and stage IIC (pT4bN0). Current guidelines recommend adjuvant chemotherapy for stage II colon cancer for the patient with high-risk factors for recurrence such as poorly differentiated histology (exclusive of those cancers that are high microsatellite instability [MSI-H]), lymphatic/vascular invasion, bowel obstruction, < 12 lymph nodes examined, perineural invasion, localized perforation, or close, indeterminate or positive margins. As for the adding oxaliplatin, according to the subgroup analysis of MOSAIC and NSABP C-07 trial, no significant benefit was found by adding oxaliplatin to 5-FU and leucovorin to stage II colon cancer [5,6]. Therefore, considering the potential risk of side effects of oxaliplatin including neuropathy, it is not recommended to adding oxaliplatin in stage II colon cancer patients. Another factors should be considered is mismatch repair or MSI testing. it should be performed before deciding adjuvant chemotherapy for stage II colon cancer, because MSI-H patients may have a good prognosis and do not benefit from 5-FU adjuvant therapy [7]. The authors tried to find which patient could omit the adjuvant chemotherapy in stage II colon cancer. And they found that the patients with only one high-risk factor for the recurrence may not have significant benefit by adjuvant chemotherapy [8]. However, it should be interpreted cautiously, because to prove a small potential benefit of adjuvant chemotherapy in stage II colon cancer, large population are inevitably needed. In conclusion, considering all above factors, conversation between clinicians and patients regarding the potential risks and benefits with adjuvant chemotherapy for stage II colon cancers is very important for de","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"11 suppl_1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89696052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors","authors":"Min Joo Kim, Seung-hyun Baek, S. Ko","doi":"10.14216/KJCO.18020","DOIUrl":"https://doi.org/10.14216/KJCO.18020","url":null,"abstract":"Treatment of colon cancer consists of surgical resection and chemotherapy. Stage II colon cancer is categorized into a high-risk group and low-risk group for recurrence, and chemotherapy is recommended for the high-risk group [1]. High-risk factors are perineural invasion, lymphovascular emboli, lymph node harvest less than 12, T4 stage, positive resection margin, obstruction, and perforation [2-4]. There is no doubt over treatment with chemotherapy for stage II colon cancer patients having high-risk factors. However, chemotherapy could cause side effects that makes patients’ compliance lower. Physicians face this dilemma, especially with patients who are old or have severe comorbidities. Therefore, this study was designed to determine the effectiveness of chemotherapy for patients with stage II colon cancer according to the number of high-risk factors.","PeriodicalId":74045,"journal":{"name":"Korean journal of clinical oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79622728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}